It remains to be seen whether abelacimab is clinically effective for stroke prevention in people with atrial fibrillation ... a direct oral anticoagulant (DOAC), according to the AZALEA-TIMI ...

LOS ANGELES -- In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) -- though, as feared, ...

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

At 3 months, the median reduction in free factor XI levels with abelacimab at a dose of 150 ... as compared with the DOAC rivaroxaban among patients with atrial fibrillation and moderate-to ...

For people with atrial fibrillation (Afib), investigational ... lower safety risks compared with a direct oral anticoagulant (DOAC), according to the AZALEA-TIMI 71 trial. Testing two once-monthly ...

Background: The prevalence of renal disease is increasing in the U.S. Renal dysfunction increases risk of atrial fibrillation, ischemic stroke ... Among those on apixaban 5mg dose, 24.5% met criteria ...

Compared with those on the direct oral anticoagulant (DOAC) rivaroxaban, patients taking the 150-mg dose of abelacimab (Anthos Therapeutics) saw a 67% reduction in major or clinically relevant ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.